Menu
Search
|

Menu

Close
X

Sienna Biopharmaceuticals Inc SNNA.OQ (NASDAQ Stock Exchange Global Select Market)

10.47 USD
+0.52 (+5.23%)
As of 9:48 AM EST
chart
Previous Close 9.95
Open 9.78
Volume 805
3m Avg Volume 17,342
Today’s High 10.47
Today’s Low 9.78
52 Week High 25.58
52 Week Low 9.01
Shares Outstanding (mil) 21.14
Market Capitalization (mil) 205.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-2.663
FY17
-2.018
FY16
-1.064
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
--
22.95
Price to Book (MRQ)
vs sector
4.48
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
66.73
15.47
LT Debt to Equity (MRQ)
vs sector
66.73
11.13
Return on Investment (TTM)
vs sector
-45.68
13.00
Return on Equity (TTM)
vs sector
-79.77
14.69

EXECUTIVE LEADERSHIP

Frederick Beddingfield
President, Chief Executive Officer, Director, Since
Salary: --
Bonus: --
John Smither
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Majed Kheir
Vice President - Operations, Since
Salary: --
Bonus: --
Susan Lundeen
Vice President - Human Resources, Since
Salary: --
Bonus: --
Caroline Van Hove
Chief Commercial Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

30699 Russell Ranch Rd Ste 140
WESTLAKE VILLAGE   CA   91362-7327

Phone: +1818.6292256

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. It's SNA-120 is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase IIb clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself. It's SNA-125 is a topical Janus kinase 3 (JAK3)/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and pruritus. Nonclinical studies have demonstrated anti-inflammatory activity in an animal model, and a favorable safety profile.

SPONSORED STORIES